Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price was up 33.3% during trading on Thursday . The company traded as high as C$0.02 and last traded at C$0.02. Approximately 290,000 shares changed hands during trading, an increase of 139% from the average daily volume of 121,571 shares. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Stock Performance
The stock’s 50 day simple moving average is C$0.02 and its two-hundred day simple moving average is C$0.02. The company has a market capitalization of C$3.32 million, a P/E ratio of -0.75 and a beta of 0.29. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.12 and a quick ratio of 0.46.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Read More
- Five stocks we like better than Aequus Pharmaceuticals
- What Does a Stock Split Mean?
- Roblox: The Bottom Just Fell Out of the Metaverse
- Insider Trades May Not Tell You What You Think
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- CD Calculator: Certificate of Deposit Calculator
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
